Drug Discovery and Translational Medicine

Date: Thursday 28 September 2017, 08.30-10.30
Room: Europa Hall

Chairs: Matthias Schmuth, Michel Gilliet

This ESDR session is supported by educational grants from



08.30-08.50 How to Bridge from Translational in vitro assays to in vivo Efficacy
Peter Florian (Director of Pharmacology, Sanofi, Frankfurt)
08.50-09.10 Animal Models: How to Test Protease Inhibitors in vivo
Alain Hovnanian (Professor of Medical Genetics and Director of INSERM department (U781), Necker Enfants Malades Hospital, University Paris Descartes Sorbonne Cité, Paris)
09.10-09.30 Key Facts for Bench Scientists: Working with Regulators Before, During and After the Licensing Procedure
Harald Tietz (Director Global Patient Safety and Regulatory Affairs, Eli Lilly, Bad Homburg)
09.30-09.50 Promising Areas of Academia-Industry Collaboration: A personal Perspective
Ralf Paus (Professor of Cutaneous Medicine, Director of Research & Deputy Lead, Centre for Dermatology Research, University of Manchester)
09.50-10.30 Pros and Cons of Industry-Academia Collaborations
Round table debate with Peter Florian, Alain Hovnanian, Ralf Paus, Anton Stuetz, Harald Tietz

Introduced by Anton Stuetz